Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Kuppermann BD, Patel SS, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, Guo Q, Schneider S, López FJ; Brimo DDS Gen 1 Study Group. Kuppermann BD, et al. Among authors: lopez fj. Retina. 2021 Jan 1;41(1):144-155. doi: 10.1097/IAE.0000000000002789. Retina. 2021. PMID: 32134802 Clinical Trial.
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.
Callanan D, Kunimoto D, Maturi RK, Patel SS, Staurenghi G, Wolf S, Cheetham JK, Hohman TC, Kim K, López FJ, Schneider S. Callanan D, et al. Among authors: lopez fj. J Ocul Pharmacol Ther. 2018 Dec;34(10):700-709. doi: 10.1089/jop.2018.0062. Epub 2018 Nov 9. J Ocul Pharmacol Ther. 2018. PMID: 30412448 Free PMC article. Clinical Trial.
A nonhuman primate model of blue light-induced progressive outer retina degeneration showing brimonidine drug delivery system-mediated cyto- and neuroprotection.
Rajagopalan L, Ghosn C, Tamhane M, Almazan A, Andrews-Jones L, Kulkarni A, Christie LA, Burke J, López FJ, Engles M. Rajagopalan L, et al. Among authors: lopez fj. Exp Eye Res. 2021 Aug;209:108678. doi: 10.1016/j.exer.2021.108678. Epub 2021 Jun 19. Exp Eye Res. 2021. PMID: 34153289 Free article.
IL-18 Immunotherapy for Neovascular AMD: Tolerability and Efficacy in Nonhuman Primates.
Doyle SL, López FJ, Celkova L, Brennan K, Mulfaul K, Ozaki E, Kenna PF, Kurali E, Hudson N, Doggett T, Ferguson TA, Humphries P, Adamson P, Campbell M. Doyle SL, et al. Among authors: lopez fj. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5424-30. doi: 10.1167/iovs.15-17264. Invest Ophthalmol Vis Sci. 2015. PMID: 26284546
Author Response: The Role of IL-18 in the Treatment of AMD.
Doyle SL, López FJ, Humphries P, Adamson P, Campbell M. Doyle SL, et al. Among authors: lopez fj. Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8237-8. doi: 10.1167/iovs.15-18714. Invest Ophthalmol Vis Sci. 2015. PMID: 26720477 No abstract available.
Systemic administration of Abeta mAb reduces retinal deposition of Abeta and activated complement C3 in age-related macular degeneration mouse model.
Catchpole I, Germaschewski V, Hoh Kam J, Lundh von Leithner P, Ford S, Gough G, Adamson P, Overend P, Hilpert J, López FJ, Ng YS, Coffey P, Jeffery G. Catchpole I, et al. Among authors: lopez fj. PLoS One. 2013 Jun 14;8(6):e65518. doi: 10.1371/journal.pone.0065518. Print 2013. PLoS One. 2013. PMID: 23799019 Free PMC article.
294 results